PULMICORT TURBUHALER 200 MCG — DIN 00851752
BUDESONIDE : 200 MCG · ASTRAZENECA CANADA INC · POWDER (METERED DOSE) · wholesale supply in Canada
Health Canada status: MARKETED
What is PULMICORT TURBUHALER?
PULMICORT TURBUHALER 200 MCG contains BUDESONIDE : 200 MCG. It is listed in the Health Canada Drug Product Database under DIN 00851752, held by ASTRAZENECA CANADA INC, supplied as POWDER (METERED DOSE) for INHALATION administration. Health Canada currently lists it as marketed, status dated 07-Nov-2000. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PULMICORT TURBUHALER used for?
Treatment of bronchial asthma in patients who require inhaled steroids or for whom a reduction of systemic glucocorticoids is desirable.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Budesonide cost around the world?
Budesonide is listed on 13 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 20 | 81 | AUD███.██ |
| Greece | producer price (ex-factory) | 68 | 68 | EUR███.██ |
| South Africa | single exit price | 37 | 42 | ZAR███.██ |
| Czechia | max producer price (ex-factory) | 17 | 39 | CZK███.██ |
| Italy | prezzo al pubblico (classe A) | 39 | 39 | EUR███.██ |
| United States | acquisition | 5 | 35 | USD███.██ |
| Saudi Arabia | public | 30 | 31 | SAR███.██ |
| Austria | KVP (Kassenverkaufspreis) | 22 | 25 | EUR███.██ |
| Luxembourg | reimbursement | 19 | 19 | EUR███.██ |
| United Arab Emirates | public | 16 | 16 | AED███.██ |
| Bahrain | retail (max) | 10 | 16 | BHD███.██ |
| Morocco | PPV (public price) | 5 | 7 | MAD███.██ |
| United Kingdom | hospital | 2 | 2 | GBP███.██ |
420 pack listings across 290 brand entries and 12 price bases, refreshed 08 Sep 2026. Ranges span every Budesonide pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Budesonide in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
3 holders have a Canadian DIN containing Budesonide, across 12 DINs, of which 12 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| ASTRAZENECA CANADA INC | 6 | 6 | PULMICORT NEBUAMP 0.125 MG/ML, PULMICORT NEBUAMP 0.25 MG/ML, PULMICORT NEBUAMP 0.5 MG/ML, PULMICORT TURBUHALER | Sourceable in Canada |
| TARO PHARMACEUTICALS INC | 3 | 3 | TARO-BUDESONIDE | Sourceable in Canada |
| TEVA CANADA LIMITED | 3 | 3 | TEVA-BUDESONIDE | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 200 MCG |
|---|---|
| Dosage form | POWDER (METERED DOSE) |
| Route | INHALATION |
| Pack configuration (monograph) | Dry powder inhaler containing 200 doses. Available in 100 mcg, 200 mcg, and 400 mcg strengths. Cannot be re-filled. |
| Storage | Store with the cover tightened at room temperature (15 - 30°C). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Budesonide |
|---|---|
| ATC code | R03BA02 |
| AHFS class | 68:04.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00851752 |
|---|---|
| DIN (unpadded, as printed on some documents) | 851752 |
| Brand name | PULMICORT TURBUHALER |
| Generic / active ingredient | BUDESONIDE : 200 MCG |
| Market authorization holder | ASTRAZENECA CANADA INC |
| Health Canada schedule | Prescription |
| ATC code | R03BA02 |
| ATC anatomical main group | R — Respiratory system |
| ATC therapeutic subgroup | R03BA |
| Current status | MARKETED |
| Status date | 07-Nov-2000 |
| Original market date | 1990-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Adults/Children >12: 400-2400 mcg/day in 2-4 divided doses. Children 6-12: 200-400 mcg/day in divided doses. Titrate to lowest effective dose. Rinse mouth after use.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Status asthmaticus; acute episodes of asthma; moderate to severe bronchiectasis; hypersensitivity to budesonide; pulmonary tuberculosis; untreated fungal, bacterial or viral respiratory infections.
Warnings and precautions
Not for acute relief. Risk of adrenal insufficiency when transferring from systemic steroids. Potential for growth suppression in children. May mask signs of infection.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
12 of 12 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| PULMICORT NEBUAMP 0.125 MG/ML | 0.125 MG | SUSPENSION | ASTRAZENECA CANADA INC | MARKETED | 02229099 |
| PULMICORT NEBUAMP 0.25 MG/ML | 0.25 MG | SUSPENSION | ASTRAZENECA CANADA INC | MARKETED | 01978918 |
| PULMICORT NEBUAMP 0.5 MG/ML | 0.5 MG | SUSPENSION | ASTRAZENECA CANADA INC | MARKETED | 01978926 |
| PULMICORT TURBUHALER | 100 MCG | POWDER (METERED DOSE) | ASTRAZENECA CANADA INC | MARKETED | 00852074 |
| PULMICORT TURBUHALER | 400 MCG | POWDER (METERED DOSE) | ASTRAZENECA CANADA INC | MARKETED | 00851760 |
| TARO-BUDESONIDE | 0.125 MG | SUSPENSION | TARO PHARMACEUTICALS INC | MARKETED | 02494264 |
| TARO-BUDESONIDE | 0.5 MG | SUSPENSION | TARO PHARMACEUTICALS INC | MARKETED | 02494280 |
| TARO-BUDESONIDE | 0.25 MG | SUSPENSION | TARO PHARMACEUTICALS INC | MARKETED | 02494272 |
| TEVA-BUDESONIDE | 0.25 MG | SUSPENSION | TEVA CANADA LIMITED | MARKETED | 02535416 |
| TEVA-BUDESONIDE | 0.125 MG | SUSPENSION | TEVA CANADA LIMITED | MARKETED | 02465949 |
2 · Same class — other molecules in ATC R03BA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Fluticasone | AERMONY RESPICLICK · APO-FLUTICASONE HFA · FLOVENT DISKUS · FLOVENT HFA · +10 more | 27 | 12 | Yes |
| Budesonide | PULMICORT NEBUAMP 0.125 MG/ML · PULMICORT NEBUAMP 0.25 MG/ML · PULMICORT NEBUAMP 0.5 MG/ML · PULMICORT TURBUHALER · +2 more | 12 | 12 | Yes |
| Mometasone | ASMANEX TWISTHALER | 3 | 3 | Yes |
| Beclometasone | ALTI-BECLOMETHASONE DIPROPIONATE INHALER 50MCG/MD · BECLODISK - PWR INH 100MCG/BLISTER · BECLODISK - PWR INH 200MCG/BLISTER · BECLODISK PWR 100MCG/BLISTER · +12 more | 17 | 2 | Yes |
| Ciclesonide | ALVESCO | 3 | 2 | Yes |
| Fluticasone Furoate | ARNUITY ELLIPTA | 2 | 2 | Yes |
| Flunisolide | BRONALIDE INHAL 250MCG/AEM | 1 | 0 | Not in Canada |
| Triamcinolone | AZMACORT | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC R03B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| R03BB | Aclidinium Bromide · Glycopyrronium Bromide · Ipratropium Bromide · Tiotropium Bromide · Umeclidinium Bromide | 37 | 15 |
| R03BC | Cromoglicic Acid · Nedocromil | 11 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is PULMICORT TURBUHALER called?
The same molecule, Budesonide, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| DuoResp Spiromax | Latin | Australia, Czechia |
| SYMBICORT TURBUHALER | Latin | Bahrain, Czechia, Saudi Arabia |
| BUFOMIX EASYHALER | Latin | Bahrain, Czechia |
| Jorveza | Latin | Australia, Czechia |
| Budenofalk | Latin | Australia, Czechia |
| GIONA EASYHALER | Latin | Czechia |
| PULMICORT | Latin | Bahrain, Czechia, Morocco |
| Pulmicort Respules | Latin | Australia |
| Pulmistad | Latin | Bahrain, Saudi Arabia |
| Breztri Aerosphere | Latin | Australia, South Africa |
| BUDENA | Latin | Morocco |
| Entocort | Latin | Australia, Bahrain, Czechia |
| AIRBUFO FORSPIRO | Latin | Czechia |
| BUDECORT | Latin | Bahrain |
| MIFLONID BREEZHALER | Latin | Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.